Business
Rani Therapeutics Appoints Kate McKinley as Chief Business Officer
SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage
About this update from Rani Therapeutics Holdings, Inc.
[{"type":"text","content":"SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has appointed Kate McKinley as its Chief Business Officer. “Kate is a seasoned industry leader, and we are thrilled to welcome her to Rani’s executive team,” said Talat Imran, Chief Executive Officer of Rani. “Kate’s expertise in corporate strategy, business development and commercialization will further strengthen our leadership team and partnering efforts, while positioning the Company for its next stage of growth. Kate will have a vital role in shaping our growth and external innovation strategy to further realize the full potential and value of our pipeline and our foundational RaniPill® platform technology.” Throughout her more than 20-year career developing high-performing teams in the biopharmaceutical industry, Ms. McKinley has held leadership roles with increasing responsibility in executive leadership, corporate strategy, business development, alliance management, commercial, supply chain and medical affairs. She has proven success securing global partnerships and executing regulatory and commercial strategies in biologics, cell therapies and small molecules across multiple therapeutic areas. Prior to joining Rani, Ms. McKinley was the Founder and Chief Executive Officer of Spark Outcomes, where she served as a fractional executive and corporate adviser for early-stage pharmaceutical, diagnostics, and health tech start-ups. In 2021, Kate was appointed to the role of Chief Executive Officer and to the Board of Directors of Elevar Therapeutics. She joined Elevar Therapeutics in 2019 as Chief Commercial Officer, where she scaled up and led the company’s global business development, commercial, medical affairs, manufacturing, supply chain, alliance management and corporate communications organizations. Earlier in her career, Ms. McKinley held roles of increasing responsibility in commercial and business development at Dendreon, AbbVie and Abbott. Ms. McKinley is a summa cum laude graduate of The University of Tulsa. She holds an MBA from The University of Tulsa’s Collins College of Business and a Bachelor of Science in Business Administration with degrees in Marketing, Manageme...